Clinical Trial

Open-Label Extension of EDG-5506 in Participants With Becker Muscular Dystrophy

Study acronym: MESA
Enrolling by Invitation Phase 2
View on ClinicalTrials.gov →
Summary
EDG-5506-203 MESA is an open-label extension study to assess the long-term effect of sevasemten (EDG-5506) on safety, biomarkers, and functional measures in adults and adolescents with Becker muscular dystrophy
Protocol Amendment History 2 changes
notable Primary completion pushed: 2029-08 -> 2031-02 2026-05-07
minor Completion pushed: 2029-08 -> 2031-02 2026-05-07
Trial Details
NCT Number NCT06066580
Lead Sponsor Edgewise Therapeutics, Inc.
Collaborators: Medpace, Inc.
Conditions Becker Muscular Dystrophy
Enrollment 260 participants
Start Date 2023-11-02
Primary Completion 2031-02 (estimated)
Study Completion 2031-02 (estimated)
Updated on ClinicalTrials.gov 2026-07-31